(Q42987508)

12 November 2017

title

T-cell vaccines that elicit effective immune responses against HCV in chimpanzees may create greater immune pressure for viral mutation (English)

1 reference

12 November 2017

author

Krzysztof Krawczyński

9

object named as

K Krawczynski

1 reference

12 November 2017

I Zubkova

1

1 reference

12 November 2017

Y H Choi

2

1 reference

12 November 2017

E Chang

3

1 reference

12 November 2017

K Pirollo

4

1 reference

12 November 2017

T Uren

5

1 reference

12 November 2017

H Watanabe

6

1 reference

12 November 2017

F Wells

7

1 reference

12 November 2017

A Kachko

8

1 reference

12 November 2017

M E Major

10

1 reference

12 November 2017

language of work or name

English

0 references

publication date

24 February 2009

1 reference

12 November 2017

1 reference

12 November 2017

volume

27

1 reference

12 November 2017

issue

19

1 reference

12 November 2017

page(s)

2594-2602

1 reference

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Cellular immune responses against hepatitis C virus: the evidence base 2002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Effect of immune globulin on the prevention of experimental hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Vaccination of chimpanzees against infection by the hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Significance of the anti-E2 response in self-limited and chronic hepatitis C virus infections in chimpanzees and in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

In vitro assay for neutralizing antibody to hepatitis C virus: Evidence for broadly conserved neutralization epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Neutralizing antibody response during acute and chronic hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Analysis of successful immune responses in persons infected with hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Determinants of viral clearance and persistence during acute hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Analysis of a successful immune response against hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

HCV Persistence and Immune Evasion in the Absence of Memory T Cell Help

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Kinetics of CD4+ and CD8+ Memory T-Cell Responses during Hepatitis C Virus Rechallenge of Previously Recovered Chimpanzees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Advances in model systems for hepatitis C virus research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Previously Infected and Recovered Chimpanzees Exhibit Rapid Responses That Control Hepatitis C Virus Replication upon Rechallenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Protection against persistence of hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Optimization and delivery of plasmid DNA for vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Receptor ligand-facilitated gene transfer: enhancement of liposome-mediated gene transfer and expression by transferrin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Differential expression and function of IgA receptors (CD89 and CD71) during maturation of dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Purifying mRNAs with a high-affinity eIF4E mutant identifies the short 3' poly(A) end phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Oral immunization with HCV-NS3-transformed Salmonella: induction of HCV-specific CTL in a transgenic mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Long-term persistence of infection in chimpanzees inoculated with an infectious hepatitis C virus clone is associated with a decrease in the viral amino acid substitution rate and low levels of heterogeneity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Hypervariable region 1 sequence stability during hepatitis C virus replication in chimpanzees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Divergent and convergent evolution after a common-source outbreak of hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Escape mutations alter proteasome processing of major histocompatibility complex class I-restricted epitopes in persistent hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

inferred from DOI database lookup

7 January 2021

based on heuristic

Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.045

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2009.02.045

1 reference

12 November 2017

1 reference